Page 91 - Amgen News Today

Unionview LLC lessened its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 12.4% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 844 shares of the medical research company’s stock after selling 120 shares during the quarter. Unionview LLC’s holdings in Amgen were worth $243,000 as of its most recent filing with […]

Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced the appointment of newly elected members of its Board of Directors (BOD) and the formation of a Scientific and Clinical...

Unionview LLC decreased its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 12.4% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 844 shares of the medical research company’s stock after selling 120 shares during the quarter. Unionview LLC’s holdings in Amgen were […]

TIAA Trust National Association increased its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 3.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 91,074 shares of the medical research company’s stock after buying an additional 2,807 shares during the quarter. TIAA Trust […]

Unionview LLC decreased its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 12.4% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 844 shares of the medical research company’s stock after selling 120 shares during the quarter. Unionview LLC’s holdings in Amgen were […]

Raymond James started coverage on shares of Amgen (NASDAQ:AMGN – Free Report) in a research note released on Thursday, MarketBeat Ratings reports. The firm issued a market perform rating on the medical research company’s stock. A number of other brokerages have also recently issued reports on AMGN. StockNews.com cut Amgen from a buy rating to […]

StockNews.com downgraded shares of Amgen (NASDAQ:AMGN – Free Report) from a buy rating to a hold rating in a report published on Thursday morning. AMGN has been the topic of a number of other research reports. Morgan Stanley reduced their price target on Amgen from $281.00 to $278.00 and set an equal weight rating on […]

Reflecting back on our time at the 13th Annual Pharma IPR Conference in Mumbai, there was a lively discussion during the panel that I moderated on Industry Insights...

BioPharma

The e-commerce veteran will be bigger, better, and more profitable, with a few surprises.